Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Accumulated Expenses: 2020-2024

Historic Accumulated Expenses for Arcutis Biotherapeutics (ARQT) over the last 5 years, with Dec 2024 value amounting to $66.8 million.

  • Arcutis Biotherapeutics' Accumulated Expenses rose 76.12% to $93.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $93.0 million, marking a year-over-year increase of 76.12%. This contributed to the annual value of $66.8 million for FY2024, which is 96.79% up from last year.
  • Latest data reveals that Arcutis Biotherapeutics reported Accumulated Expenses of $66.8 million as of FY2024, which was up 96.79% from $33.9 million recorded in FY2023.
  • In the past 5 years, Arcutis Biotherapeutics' Accumulated Expenses registered a high of $66.8 million during FY2024, and its lowest value of $15.5 million during FY2020.
  • For the 3-year period, Arcutis Biotherapeutics' Accumulated Expenses averaged around $43.0 million, with its median value being $33.9 million (2023).
  • Data for Arcutis Biotherapeutics' Accumulated Expenses shows a peak YoY spiked of 96.79% (in 2024) over the last 5 years.
  • Yearly analysis of 5 years shows Arcutis Biotherapeutics' Accumulated Expenses stood at $15.5 million in 2020, then skyrocketed by 65.18% to $25.5 million in 2021, then grew by 10.90% to $28.3 million in 2022, then climbed by 19.84% to $33.9 million in 2023, then spiked by 96.79% to $66.8 million in 2024.